missing translation for 'onlineSavingsMsg'
Learn More
Learn More
BMP-7 Mouse anti-Human, Clone: 164313, R&D Systems™
Mouse Monoclonal Antibody has been used in 1 publication
Brand: R&D Systems MAB3542-SP
This item is not returnable.
View return policy
Description
BMP-7 Monoclonal specifically detects BMP-7 in Human samples. It is validated for Immunohistochemistry, Neutralization, ELISA Capture (Matched Antibody Pair).Specifications
| BMP-7 | |
| Monoclonal | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| BMP7, BMP-7, bone morphogenetic protein 7, Eptotermin alfa, OP-1, OP-1OP1, Osteogenic protein 1 | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 655 | |
| Reconstitute at 0.5 mg/mL in sterile PBS. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG1 |
| Immunohistochemistry, Neutralization, ELISA | |
| 164313 | |
| Immunohistochemistry 8-25 ug/mL, Neutralization 4-12 ug/mL, ELISA Capture (Matched Antibody Pair) 2-8 ug/mL | |
| P18075 | |
| BMP7 | |
| Chinese hamster ovary cell line CHO-derived recombinant human BMP-7 Arg292-His431 Accession # P18075 | |
| 25 μg | |
| Primary | |
| Detects human BMP-7 in ELISAs. In ELISAs, this antibody shows approximately 25-50% cross-reactivity with recombinant human (rh) BMP-6 and no cross-reactivity with rhBMP-2, -3, -4, -5, or -8. | |
| Human | |
| Purified |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?